Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products, according to the Associated Press.
Eli Lilly said it will expand the Kenosha County factory it bought early this year to help meet growing demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year’s third quarter.
The drugmaker plans to start construction of the expansion next year. The company has reportedly slated more than $23 billion to construct, expand, or acquire manufacturing sites worldwide since 2020.
